Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats

We assessed the effects of lodenafil on hemodynamics and inflammation in the rat model of monocrotaline-induced pulmonary hypertension (PH). Thirty male Sprague-Dawley rats were randomly divided into three groups: control; monocrotaline (experimental model); and lodenafil (experimental model followe...

Descripción completa

Detalles Bibliográficos
Autores principales: Polonio, Igor Bastos, Acencio, Milena Marques Pagliareli, Pazetti, Rogério, de Almeida, Francine Maria, da Silva, Bárbara Soares, Pereira, Karina Aparecida Bonifácio, Souza, Rogério
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Pneumologia e Tisiologia 2014
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201173/
https://www.ncbi.nlm.nih.gov/pubmed/25210965
http://dx.doi.org/10.1590/S1806-37132014000400010
Descripción
Sumario:We assessed the effects of lodenafil on hemodynamics and inflammation in the rat model of monocrotaline-induced pulmonary hypertension (PH). Thirty male Sprague-Dawley rats were randomly divided into three groups: control; monocrotaline (experimental model); and lodenafil (experimental model followed by lodenafil treatment, p.o., 5 mg/kg daily for 28 days) Mean pulmonary artery pressure (mPAP) was obtained by right heart catheterization. We investigated right ventricular hypertrophy (RVH) and IL-1 levels in lung fragments. The number of cases of RVH was significantly higher in the monocrotaline group than in the lodenafil and control groups, as were mPAP and IL-1 levels. We conclude that lodenafil can prevent monocrotaline-induced PH, RVH, and inflammation.

Ejemplares similares